TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Telomir Pharmaceuticals, Inc. ( (TELO) ).
Telomir Pharmaceuticals announced that its compound Telomir-1 selectively kills aggressive triple-negative breast cancer cells by disrupting iron-dependent cellular energy pathways and mitochondrial function. This discovery highlights the potential of Telomir-1 to exploit a metabolic vulnerability in these cancer cells, offering a promising avenue for treatment while sparing healthy tissue. The company plans to expand its studies to other cancer types and conduct further animal studies in preparation for an IND submission.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focusing on developing therapies that target epigenetic drivers of cancer, aging, and age-related diseases.
Average Trading Volume: 4,977,257
Technical Sentiment Signal: Sell
Current Market Cap: $45.84M
Learn more about TELO stock on TipRanks’ Stock Analysis page.